ArticleMolecular medicine reports2016
Effects of ophiopogonin B on the proliferation and apoptosis of SGC‑7901 human gastric cancer cells.
Article in Molecular medicine reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Pharmacological mechanisms of traditional Chinese medicine in treating gastric cancer: a focus on the ferroptosis regulation.Frontiers in pharmacology · 2025Pooled it
- Ophiopogonin‑B targets PTP1B to inhibit the malignant progression of hepatocellular carcinoma by regulating the PI3K/AKT and AMPK signaling pathways.Molecular medicine reports · 2022Article
- Ophiopogonin B induces gastric cancer cell death by blocking the GPX4/xCT-dependent ferroptosis pathway.Oncology letters · 2022Article
- Synthetic and Naturally Occurring Heterocyclic Anticancer Compounds with Multiple Biological Targets.Molecules (Basel, Switzerland) · 2021Review
- Potential of Bioactive Food Components against Gastric Cancer: Insights into Molecular Mechanism and Therapeutic Targets.Cancers · 2021Review
- Ophiopogonin B induces reactive oxygen species‑dependent apoptosis through the Hippo pathway in nasopharyngeal carcinoma.Molecular medicine reports · 2021Article
- Advances in Molecular Mechanisms for Traditional Chinese Medicine Actions in Regulating Tumor Immune Responses.Frontiers in pharmacology · 2020Review
- CCL2-CCL5/CCR4 contributed to radiation-induced epithelial-mesenchymal transition of HPAEpiC cells via the ERK signaling pathways.American journal of translational research · 2019Article
- Development of Certain Protein Kinase Inhibitors with the Components from Traditional Chinese Medicine.Frontiers in pharmacology · 2016Review
- A prospective review of the health-promoting potential of Jing Si Herbal Tea.Tzu chi medical journalReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ophiopogonin B (OP‑B) is a bioactive component of Radix Ophiopogon japonicus, which is often used in traditional Chinese medicine to treat cancer. The present study aimed to investigate the antitumor activity of OP‑B in gastric cancer. Cell Counting kit‑8, flow cytometry with Annexin V‑fluorescein isothiocyanate, Hoechst staining, mitochondrial membrane potential (MMP) detection, and reactive oxygen species (ROS) assay were used to detect the biological function of SGC‑7901 gastric cancer cells. The results demonstrated that high concentrations of OP‑B (5, 10 and 20 µmol/l) exerted potent antiproliferative effects on SGC‑7901 cells in a dose‑dependent manner. Furthermore, apoptotic rates were increased and cell morphology was altered following treatment with OP‑B. In addition, OP‑B‑induced apoptosis of SGC‑7901 cells was associated with loss of MMP and increased ROS generation. Western blotting indicated that treatment with OP‑B increased the protein expression levels of caspase‑3 and B‑cell lymphoma 2 (Bcl‑2)‑associated X protein, whereas the expression levels of Bcl‑2 and the phosphorylation levels of extracellular signal‑regulated kinases 1/2 and c‑Jun N‑terminal kinases 1/2 were decreased. These results suggest that OP‑B may be considered a potential inhibitor of gastric cancer progression, and may be used as an alternative compound for its treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.